Several comments to my previous post on the new Concerta generic (made available only in the U.S., not Canada) suggest that this “authorized generic” might not be exactly the same as the brand name, as claimed by the manufacturer. Then again, a news report this morning leaves me wondering if some people have received counterfeit pharmaceuticals.
A recap from the previous post:
The U.S. generic for Concerta is methylphenidate hydrochloride extended-release tablets. It is a co-licensed product by exclusive agreement — that is, a deal between the original manufacturer (Ortho-McNeil) and the pharmaceutical marketing arm of Watson Laboratories.
Both brand-name Concerta and the so-called “authorized generic” are manufactured in the same plant, said the Ortho-McNeil spokesperson by phone. And, this authorized generic is both bioequivalent and clinically equivalent. Does that mean it’s the exact same medication? I think so, but I cannot be absolutely sure at this point.
This morning, the California Report’s Sarah Varney explained a California law designed to protect consumers from counterfeit medications (the law has been fought by trade groups for years):
A state law meant to thwart counterfeit prescription drugs is finally set to go into effect 16 years after it first passed. The electronic tracking system will make business harder for those who sell fake drugs. (Listen to this short report here.)
I’ve found no data documenting counterfeit problems with the more expensive stimulant medications (Concerta, Vyvanse, etc.). And readers’ comments offer no details on where the medication was purchased. Stay tuned. And please share any tidbits you learn.